Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting

Core Insights - Candel Therapeutics, Inc. announced that an abstract was accepted for oral presentation at the AUA 2026 Annual Meeting, focusing on new data from its phase 3 clinical trial of aglatimagene besadenovec in patients with localized prostate cancer [1] Company Overview - Candel is a clinical-stage biopharmaceutical company developing multimodal biological immunotherapies aimed at eliciting systemic anti-tumor immune responses to combat cancer [4] - The company has two clinical-stage platforms based on genetically modified adenovirus and herpes simplex virus (HSV) gene constructs [4] - Aglatimagene besadenovec (CAN-2409) is the lead candidate from the adenovirus platform, having completed successful phase 2a trials in non-small cell lung cancer and pancreatic ductal adenocarcinoma, as well as a pivotal phase 3 trial in localized prostate cancer [4] Clinical Trials and Regulatory Designations - The phase 3 trial of aglatimagene in localized prostate cancer was conducted under a Special Protocol Assessment with the FDA, which granted Fast Track and Regenerative Medicine Advanced Therapy Designations for this treatment [4] - Linoserpaturev (CAN-3110), the lead candidate from the HSV platform, is currently in a phase 1b trial for recurrent high-grade glioma and has received Fast Track and Orphan Drug Designations from the FDA [5] Presentation Details - The presentation at the AUA will be titled "Extended follow-up shows accumulating benefit for patients treated with CAN-2409+prodrug in combination with standard of care external beam radiation in men with localized prostate cancer: update from PrTK03 randomized phase 3 clinical trial" [8] - It is scheduled for May 15, 2026, from 11:30 AM to 11:40 AM ET at the Walter E. Washington Convention Center in Washington, D.C. [8]